The Assurex Health Scientific Advisory Board guides continuing innovation of GeneSight® technology.
Tracy A. Glauser, M.D.
Tracy A. Glauser is Associate Director, Cincinnati Children’s Research Foundation and Professor of Pediatrics, Director of the Comprehensive Epilepsy Center, and Co-Director of the Genetic Pharmacology Service at Cincinnati Children’s Hospital Medical Center. Dr. Glauser currently directs the NIH funded Childhood Absence Epilepsy clinical trial involving 29 pediatric centers around the United States and has been the principal investigator on multiple NIH grants. Dr. Glauser’s fields of expertise are pediatric neurology, pediatric epilepsy, clinical pharmacology, and pharmacogenomics, and he has published more than 175 articles and book chapters, and is a co-inventor of Assurex technology. Dr. Glauser received his M.D. from Jefferson Medical College in Philadelphia, Pennsylvania and he completed his residency in pediatrics at the John Hopkins Hospital in Baltimore, Maryland. Dr. Glauser also completed a fellowship in child neurology at The Children’s Hospital of Philadelphia, University of Pennsylvania in Philadelphia, Pennsylvania, and a fellowship in epilepsy and electroencephalography at St. Louis Children’s Hospital in St. Louis, Missouri.
To learn more about Dr. Glauser, please visit Cincinnati Children’s Hospital Medical Center website.
Learn more about Dr. Glauser’s research at PubMed.
James L. Kennedy, M.D., FRCP(C), FRSC
James L. Kennedy is Director of Neuroscience Research at the Tannenbaum Centre for Pharmacogenetics, and Professor in the Department of Psychiatry at the University of Toronto. Dr. Kennedy has training in three major areas: neuroscience, clinical psychiatry, and molecular genetics, with his main research focus over the past 20 years in the identification of susceptibility genes for psychiatric disorders. Dr. Kennedy has published more than 440 scientific articles with over 20,000 citations, and he is an active lecturer at numerous international conferences. A major current project led by Dr. Kennedy is examining a large sample of 20,000 patients to determine the usefulness and cost-benefit of pharmacogenomic testing applied to the clinical choice and dosage of psychiatric medications. Dr. Kennedy received his B.Sc. and M.Sc. from York University in Toronto, Canada and his M.D. from the University of Calgary in Alberta, Canada.
To learn more about Dr. Kennedy, please visit the CAMH website.
Learn more about Dr. Kennedy’s research at PubMed.
Lawrence J. Lesko, Ph.D., FCP
Lawrence J. Lesko is Clinical Professor and Director of the Center for Pharmacometrics and Systems Pharmacology at the University of Florida’s Research and Academic Center in Orlando. Dr. Lesko served as Director of the Office of Clinical Pharmacology in the Food and Drug Administration’s Center for Drug Evaluation and Research from 1995-2011. He was also Chair of the Clinical Pharmacology Coordinating Subcommittee of the FDA’s Medical Policy Coordinating Committee and started the FDA’s Voluntary Genomics Data Submission Program and Mechanistic Drug Safety Programs. Dr. Lesko has published more than 200 peer-reviewed manuscripts, and is frequently an invited speaker in clinical pharmacology, personalized medicine, pharmacometrics, and systems pharmacology. His research includes drug development and regulatory science, quantitative clinical pharmacology, and pharmacogenomics. Dr. Lesko received his B.S. and Ph.D. degrees from Temple University in Philadelphia, Pennsylvania and Advanced Executive Training at the Federal Executive Institute in Charlottesville, Virginia.
To learn more about Dr. Lesko, please visit University of Florida, College of Pharmacy’s website.
Learn more about Dr. Lesko’s research at PubMed.
Wolfgang Sadee, Dr.rer.nat
Wolfgang Sadee is the Felts Mercer Professor of Medicine and Pharmacology, Chair, Department of Pharmacology, Director of the Center for Pharmacogenomics, and Professor of Psychiatry, Pharmacy, and Medical Genetics at The Ohio State University. He is also a DHLRI investigator at the Davis Heart & Lung Research Institute and a member at the OSU Comprehensive Cancer Center. As a member of the NIGMS Pharmacogenomics Research Network III, Dr. Sadee is leading the project “Expression Genetics in Drug Therapy”. Dr. Sadee’s research focuses on pharmacogenomics, employing genomics technologies to discover regulatory variants affecting disease risk and drug response, and developing biomarker tests for optimizing individualized therapies. He has published over 350 research papers, chapters, and monographs, and served as founding editor of Pharmaceutical Research and The AAPS Journal. Dr. Sadee received his Ph.D. in Pharmaceutical Chemistry at the Free University of Berlin in Berlin, Germany.
To learn more about Dr. Sadee, please visit The Ohio State University, College of Medicine’s website.
Learn more about Dr. Sadee’s research at PubMed.